Seroprevalencia de anticuerpos para virus linfotrópicos humanos (HTLV I/II) en donantes de sangre de una clínica de Bogotá, Colombia. 1999-2004

Oscar Martínez-Nieto, Mario Isaza-Ruget, Nancy Rangel-Espinosa, Olga L. Morales-Reyes

Producción: Contribución a una revistaArtículorevisión exhaustiva

8 Citas (Scopus)

Resumen

Objective: This study was aimed at determining anti-human T-lymphotropic virus I/II (HTLV I/II) seroprevalence amongst blood-donors at the Clínica Reina Sofía in Bogotá, Colombia, between 1999 and 2004. Methods: All people donating blood at the Clínica Reina Sofía were selected for anti-HTLV I/II testing; a survey was carried out which focused on risk factors. All blood donations were screened by using enzyme immunolinked assay (ELISA); repeatedly reactive serum samples were confirmed as being HTLV I or HTLV II by using Western blot (WB). Results: 8 913 blood donors, 5 883 (66 %) males and 3,030 (34 %) females having a mean age of 37 were included in the study; 26 (0,3 %) were repeatedly reactive in ELISA tests, 6 (0,07 %) of whom were confirmed by using Western blot (WB). Our findings revealed 0,07 % HTLV seroprevalence amongst blood-donors, in line with other European and South-American countries. Conclusion: Although our findings suggest low HTLV I/II seroprevalence, blood-donors should be routinely screened to minimise transmission due to occult HTLV I/II infection in Colombia.

Título traducido de la contribuciónHuman T-lymphotropic virus (HTLV I/II) seroprevalence amongst blood-donors in a hospital in Bogotá, Colombia, between 1999 and 2004
Idioma originalEspañol
Páginas (desde-hasta)253-261
Número de páginas9
PublicaciónRevista de Salud Publica
Volumen9
N.º2
DOI
EstadoPublicada - 2007
Publicado de forma externa

Palabras clave

  • Blood banks
  • Blood transfusion
  • Blood-donors
  • Human T-lymphotropic virus 1
  • Human T-lymphotropic virus 2 (source: MeSH, NLM)

Huella

Profundice en los temas de investigación de 'Seroprevalencia de anticuerpos para virus linfotrópicos humanos (HTLV I/II) en donantes de sangre de una clínica de Bogotá, Colombia. 1999-2004'. En conjunto forman una huella única.

Citar esto